Cadila fund-raising plan stokes deal speculation
This article was originally published in Scrip
India's Cadila Healthcare is seeking shareholder approval to raise up to INR100bn ($1.6bn), fuelling some speculation that it may be prepping for a small-to-medium sized acquisition in the future.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.